Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02609568 · ClinicalTrials.gov registry record
Salivary Biomarkers in Pediatric Traumatic Brain Injury
A clinical trial, sponsored by Valleywise Health.
- Completed
- Registry status
- 77
- Enrollment target
NCT02609568: Completed study, sponsored by Valleywise Health.
NCT02609568 is a clinical trial that has completed, run by Valleywise Health. The registered enrollment target is 77 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02609568 has completed, sponsored by Valleywise Health.
- COMPLETED
- Registry status
- 77 participants
- Enrollment target
Study Summary
By studying individual biomarkers in body fluids such as saliva, there is a potential for detecting injury to the brain resulting from an acute traumatic even that may not be detectable by conventional neuroimaging like CT scans.
Primary Outcome
Within 24 hours of an acute isolated TBI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2014-04-16 |
| Est. Completion | 2017-03-30 |
What the finished NCT02609568 record still lists
NCT02609568 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 77 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02609568 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02609568 about?
NCT02609568 is a clinical study titled "Salivary Biomarkers in Pediatric Traumatic Brain Injury". By studying individual biomarkers in body fluids such as saliva, there is a potential for detecting injury to the brain resulting from an acute traumatic even that may not be detectable by conventional neuroimaging like CT scans.
What is the current status of trial NCT02609568?
This trial is currently completed. The enrollment target is 77 participants. The study started on 2014-04-16. Estimated completion is 2017-03-30.
Who is sponsoring clinical trial NCT02609568?
This trial is sponsored by Valleywise Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI